Contrary to existing understanding, long-term follow-up of patients with two types of breast tissue abnormalities suggests that both types of abnormalities have the same potential to progress to breast cancer.
A phase III study of Imbruvica in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma was stopped early following an interim analysis and at the recommendation of an independent data monitoring committee, which concluded the study demonstrated a significant difference in progression-free survival compared to ofatumumab.
A phase III trial of Abraxane extended overall survival in metastatic pancreatic cancer, with some patients surviving longer than three years, when used in combination with gemcitabine.
